Inclusion Criteria:

- Diagnosis of solid tumor that overexpresses epidermal growth factor receptor (EGFR)
including, but not limited to, the following:

- Breast cancer

- Lung cancer

- Colon cancer

- Pancreatic cancer

- Head and neck cancer

- Kidney cancer

- Sarcoma

- Advanced disease

- Must have failed or become intolerant to prior standard therapy and is no longer
likely to respond to such therapy

- Measurable or nonmeasurable disease

- ECOG performance status 0-1

- ANC ≥ 1,500/mm³

- Platelet count > 100,000/mm³

- Hemoglobin > 9 g/dL

- Bilirubin < 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase < 3.0 times ULN (5.0 times ULN if liver has tumor involvement)

- Aspartate aminotransferase (AST) and alanine aminotransferase (*ALT) < 3.0 times
upper limit of normal (ULN) (5.0 times ULN if liver has tumor involvement)

- Creatinine clearance > 30 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after
completion of study treatment

- Recovered from all prior therapy

- Prior systemic chemotherapy, immunotherapy, or biological therapy allowed

- At least 14 days since prior radiotherapy or systemic therapy

- At least 30 days since prior investigational agents

- At least 14 days since other prior investigational drugs (for reasons other than the
treatment of cancer)

Exclusion Criteria:

- Untreated or symptomatic central nervous system (CNS) metastases

- Concurrent serious systemic disorders (e.g., active infection) that, in the opinion
of the investigator, would compromise the safety of the patient or compromise the
patient's ability to complete the study

- Uncontrolled diabetes

- Myocardial infarction within the past 6 months

- New York Heart Association (NYHA) class III or IV heart failure

- Uncontrolled angina

- Severe uncontrolled ventricular arrhythmias

- Evidence of acute ischemia or active conduction system abnormalities by ECG

- Peripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade >
2

- Known hypersensitivity to bortezomib, boron, or mannitol

- Serious medical or psychiatric illness likely to interfere with study participation

- Prior bortezomib and/or cetuximab

- Concurrent filgrastim (G-CSF) or other hematologic support during course 1 of study
treatment